Terms: = Pancreatic cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Diagnosis
3 results:
1. FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Marschner N; Hegewisch-Becker S; Reiser M; von der Heyde E; Bertram M; Hollerbach SH; Kreher S; Wolf T; Binninger A; Chiabudini M; Kaiser-Osterhues A; Jänicke M;
Int J Cancer; 2023 Feb; 152(3):458-469. PubMed ID: 36053905
[TBL] [Abstract] [Full Text] [Related]
2. ttd consensus document on the diagnosis and management of exocrine pancreatic cancer.
Benavides M; Abad A; Ales I; Carrato A; Díaz Rubio E; Gallego J; García-Foncillas J; Grávalos C; Laquente B; Pericay C; Rivera F; Tabernero J; Aranda E
Clin Transl Oncol; 2014 Oct; 16(10):865-78. PubMed ID: 24728654
[TBL] [Abstract] [Full Text] [Related]
3. Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management: a guideline of the ttd group.
Segura PP; Ponce CG; Ramón Y Cajal T; Blanch RS; Aranda E
Clin Transl Oncol; 2012 Aug; 14(8):553-63. PubMed ID: 22855135
[TBL] [Abstract] [Full Text] [Related]
